t v
play

T V De v eloping No v el Sol ut ion s To T r ea t H u man Papilloma - PowerPoint PPT Presentation

Sep 02, 2023 •543 likes •653 views

VITTAIL Ltd. T V De v eloping No v el Sol ut ion s To T r ea t H u man Papilloma Vi rus - Rela t ed Cance rs and P r o st a t e Cance r Targeting Major Unmet Medical Needs Therapeutic development based on a key discovery by the founders: The

  1. VITTAIL Ltd. T V De v eloping No v el Sol ut ion s To T r ea t H u man Papilloma Vi rus - Rela t ed Cance rs and P r o st a t e Cance r

  2. Targeting Major Unmet Medical Needs Therapeutic development based on a key discovery by the founders: The Company is targeting treatments for prostate cancer and HPV-related cancers that will be: a. A first in class, small molecule inhibitor of a key protein (E6AP) b. Developed to preclinical stage prior to licensing c. Protected by intellectual property, including composition of matter patent(s) Risk minimised through: Experienced management team (drug discovery methodology, global innovators of the underlying knowhow) Experienced Board with extensive biotech start-up and development track record Identification of key biomarkers and the clinical nexus between E6AP and multiple cancer Established contracts with key service providers (SYNthesis Research, Peter Mac). Established collaborations for disease models and clinical consultation Currently no competing IP

  3. Target Markets Life expectancy HPV Global Percentage of Related New Cases Cancers 5 year survival Market Size Cancers (pa) Treatable by Vittail 67.1% - all cases Cervical Cancer 528,000 95 % 17.3% - metastatic disease 51 % Oral cavity and 60.7% - all cases 358,000 44% Larynx 34.3% - metastatic disease 67% - all cases Penis 30% -metastatic Anal Cancer 40,000 88% 41 % disease 31 % Oral Cavity and 64.5% - all cases 31% 96,000 Oral and Vagina Pharynx Cancer 38.5% - metastatic disease Pharynx and Vulva Vaginal and Vulvar 72.1% - all cases 49,000 41% Cancers 17.4% - metastatic disease 95% - all cases Penile Cancer # 26,000 51% 44 % 73% - metastatic disease 88 % 88 % 18 % Oral Cervix Prostate Anus Percentage Life expectancy and Larynx Global New Other Cancers Treatable by 5 year survival Cases (pa) Vittail 98.6% for all 18% Prostate Cancer 200,000 29.8% metastatic disease

  4. Founders: Experienced Innovators Tom Peat, Ph.D. John Deadman, Ph.D. Ygal Haupt, Ph.D. PhD - Walter and Eliza Hall, discovered Bmi1; BS in Biochemistry and Biophysics - UC Berkeley; PhD BSc in medicinal chemistry, PhD in the field of in Molecular, Cellular & Biophysical Studies - Columbia postdoctoral research at the Weizmann drug discovery. University. Institute; Major discovery of the degradation Over 25 years experience in Drug Discovery and First scientist hired by SGX Pharmaceuticals, appointed of p53 by Mdm2. Development. Director of Structural Biology. World-leading researcher in tumour Managed multidisciplinary teams globally for VP of Proteomics at OpenEye Scientific Software, suppression with a focus on cancer biology of research projects and regulatory purposes established San Diego facility. the ubiquitin proteasome system. under GMP. Established in CSIRO fragment screening program: Led 2 large consortia (Europe and Australia Developed drugs under IND to Phase III clinical used by multiple international biotech and with over $27m in research funding), trials. pharmaceutical companies. supervised over 80 students/research staff. Experience at management and board level in Helped develop inhibitors: PRMT5 sold to Merck USA Multiple awards/fellowships (including biotech in Europe, Australasia and China. in 2016 for US$500M, other inhibitors sold to Pfizer in NHMRC and the Victorian Endowment for 2018 for US$490M. International biotech consultant with multiple Experienced in solving >1000 protein structures, Science Knowledge and Innovation). publications, grants and inventions (multiple multiple publications & co-founder of MecRX & Vittail. patents including granted patents). VITTAIL has an experienced clinical advisory panel including: SAB •Prof. S. Sandhu for castration resistant prostate cancer •Prof. B. Solomon for HPV driven cancers

  5. Fragment-Based Drug Design (FBDD) screening process Partner Organisations’ Roles Biological assays CSIRO PeterMac Fragment Libraries AlphaScreen activity/counter- screen/selectivity) ubiquitination, pre-clinical mouse models CSIRO Biophysical assays SYNthesis Bio21 SPR and STD NMR Medicinal chemistry CDCO Fragment optimisation physicochemical optimisation (ADMET/ “drug likeness”) X-ray crystallography Synchrotron Fragments and ligands using CSIRO Australian Synchrotron VITTAIL Preclinical lead drug

  6. The Target: E6-Associated Protein (E6AP) E6AP is critical for high-risk HPV-related and prostate cancers E6AP ordinarily regulates the expression of three key tumour suppressors in the body - p53, PML and p27. In cancers E6AP is ‘over activated’ causing the destruction of tumour suppressors. VITTAIL’s therapeutic approach is to inhibit E6AP to restore the body’s tumour suppressive capacity.

  7. E6AP promotes cancer by degrading the patient’s tumour suppressing protein (PML) in prostate cancer 100 Partial Major cancers in which the 80 Loss key target of E6AP is lost. These are relevant cancers Complete 60 for VITTAILS’s novel Loss therapeutic approach 40 20 Lung 0 Colon Breast Prostate Lymphoma Germ Cell CNS

  8. Targeting E6AP inhibits prostate cancer prolonging the life of experimental mice. The growth of human prostate cancer is significantly inhibited by depleting E6AP in experimental models. Depletion of E6AP restores the body’s anti-cancer activities. Without With E6AP E6AP

  9. Timeline for Drug Development Multiple Proof Hits/Early Leads of concept Identified data Licensing event 2020-21 2021-2022 2023 2024 Assay Platform Fragment Compound Test Compound Negotiate Establishment Screen Optimization as E6AP Licensing inhibitor in transaction/ cancer models M&A Capital - efficient structure & key discovery partnership with CSIRO provides a rapid path to a commercialisation event

  10. Offer Summary $ 1.5 Million Amount to be Raised ( with the ability to accept over subscriptions ) Offer Price Per $ 1 Prefence Share Number of New Preference 1.5 Million Shares Being Offered ( with the ability to accept over subscriptions ) Valuation of ViITTAIL $ 1.5 Million pre - raising 2 Million Preference Shares Total Number of Shares After Raising ( including Ordinary Shares and 1 Million Ordinary Shares Preference Shares ) Additional shares will also be issued if there are any oversubscriptions Indicative Capitalisation of $ 3 Million Company After Raising

Recommend

More recommend